Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Hashimoto, M ^a   Suizu, F ^a   Tokuyama, W ^b   Noguchi, H ^c   Hirata, N ^a   Matsuda Lennikov, M ^a   Edamura, T ^a   Masuzawa, M ^d   Gotoh, N ^e   Tanaka, S ^f   Noguchi, M ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEINE KEIJINKAI HOSPITAL   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Angiosarcoma; Protooncogene TCL1b; Transgenic mice

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CARCINOGENICITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE INDUCTION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; T CELL LEUKEMIA; TRANSGENIC MOUSE;

EID: 84884811538     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.30     Document Type: Article

References (55)

1. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274. (Pubitemid 46962095)
2. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003; 546: 108-112. (Pubitemid 36782290)
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657. (Pubitemid 34579158)
4. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262. (Pubitemid 37329790)
5. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate- dependent activation of protein kinase B. Science 1998; 279: 710-714. (Pubitemid 28144551)
6. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
7. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101. (Pubitemid 40262113)
8. Stern MH, Soulier J, Rosenzwajg M, Nakahara K, Canki-Klain N, Aurias A et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8: 2475-2483. (Pubitemid 23252377)
9. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530-12534.
10. Cao D, Lane Z, Allan RW, Wang P, Guo CC, Peng Y et al. TCL1 is a diagnostic marker for intratubular germ cell neoplasia and classic seminoma. Histopathology 2010; 57: 147-167.
11. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J 2007; 21: 2273-2284. (Pubitemid 47230657)
12. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
13. Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000; 97: 3028-3033. (Pubitemid 30183249)
14. Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer 2005; 5: 640-648. (Pubitemid 41081389)
15. Auguin D, Barthe P, Royer C, Stern MH, Noguchi M, Arold ST et al. Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family protooncoproteins. J Biol Chem 2004; 279: 35890-35902. (Pubitemid 39100596)
16. Auguin D, Barthe P, Auge-Senegas MT, Stern MH, Noguchi M, Roumestand C. Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates. J Biomol NMR 2004; 28: 137-155. (Pubitemid 38232793)
17. Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 1999; 96: 2949-2951. (Pubitemid 29148824)
18. Hallas C, Pekarsky Y, Itoyama T, Varnum J, Bichi R, Rothstein JL et al. Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes. Proc Natl Acad Sci USA 1999; 96: 14418-14423. (Pubitemid 30000665)
19. Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 1998; 92: 368-373. (Pubitemid 28323696)
20. Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998; 95: 3885-3889. (Pubitemid 28173223)
21. Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002; 99: 14392-14397. (Pubitemid 35257682)
22. Zwolinska K. Host genetic factors associated with susceptibility to HIV infection and progression of infection. Postepy Hig Med Dosw (Online) 2009; 63: 73-91.
23. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868. (Pubitemid 29165088)
24. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868. (Pubitemid 29003722)
26. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012; 40: D109-D114.
27. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010; 38: D355-D360.
28. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29. (Pubitemid 30257031)
29. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 1998; 95: 14950-14955. (Pubitemid 29003737)
30. Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001; 20: 4419-4423. (Pubitemid 32726886)
31. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 1989; 79: 269-277. (Pubitemid 19183206)
32. Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci 2009; 111: 4-18.
33. Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C et al. Inhibition of Akt kinase activity by a peptide spanning the bA strand of the proto-oncogene TCL1. J Biol Chem 2004; 279: 53407-53418. (Pubitemid 40051845)
34. Kunstle G, Laine J, Pierron G, Kagami Si S, Nakajima H, Hoh F et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002; 22: 1513-1525. (Pubitemid 34150787)
35. Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem 2002; 277: 3743-3751. (Pubitemid 34953249)
36. Narducci MG, Fiorenza MT, Kang SM, Bevilacqua A, Di Giacomo M, Remotti D et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci USA 2002; 99: 11712-11717. (Pubitemid 34994464)
37. Pekarsky Y, Hallas C, Palamarchuk A, Koval A, Bullrich F, Hirata Y et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci USA 2001; 98: 3690-3694. (Pubitemid 32249832)
38. Gold MR. Akt is TCL-ish: implications for B-cell lymphoma. Trends Immunol 2003; 24: 104-108. (Pubitemid 36263090)
39. Enzler T, Kater AP, Zhang W, Widhopf 2nd GF, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-4476.
40. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255.
41. Teitell M, Damore MA, Sulur GG, Turner DE, Stern MH, Said JW et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci USA 1999; 96: 9809-9814. (Pubitemid 29398814)
42. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464. (Pubitemid 41637985)
43. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010; 11: 983-991.
44. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66: 915-920. (Pubitemid 43165958)
45. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997; 276: 1848-1850. (Pubitemid 27443659)
46. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010; 251: 1098-1106.
47. Perry B, Banyard J, McLaughlin ER, Watnick R, Sohn A, Brindley DN et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007; 143: 504-506. (Pubitemid 46631649)
48. Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 2005; 102: 128-133. (Pubitemid 40094440)
49. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170. (Pubitemid 44175906)
50. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006; 103: 1475-1479. (Pubitemid 43191190)
51. Lin N, Uchi H, Moroi Y, Fukiwake N, Dainichi T, Takeuchi S et al. Significance of the expression of phosphorylated signal transducer and activator of transcription-3, -Akt, and -cyclin D1 in angiosarcoma. J Dermatol Sci 2007; 48: 64-66. (Pubitemid 47284807)
52. Noguchi M, Obata T, Suizu F. Curr Signal Ther 2008; 3: 138-151.
53. Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell 2009; 17: 800-810.
54. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996; 271: 31372-31378. (Pubitemid 26408588)
55. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M et al. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol 2010; 176: 2139-2149.